CENTRAL PAX CENTER

JUL 3 0 2004

I hereby certify that this correspondence is being faceimile transmitted to the U.S. Patent and Trademark Office (fax no. 1-703-872-9306) on July 30, 2004. Mame of person signing this certificate: Kevin L. Pontius

IN THE UNITED STATES PATEST AND TRADEMARK OFFICE

In re Application of

Docket No.: UNME-0118-1

Samuel H. SLISHMAN

Appln. No.: 10/074,009

Filed: Feb. 14,2002

Conf. No.: 9066

Title: Per Kilo Doser

Group Art Unit:

Examiner: N. Mendez

ELECTION

M/S Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In reply to the Office Action of July 13, 2004, Applicant hereby elects Invention I (a syringe) and Species 1 (shown in Fig. 1).

The election of species requirement is traversed to the extent that Applicant disagrees with the Examiner's contention that only claim 1 is generic. Applicant respectfully submits that claims 1, 7, 28-30, 34, and 40-44 are generic because none of them recite limitations that are unique to any of the · identified species shown in Figs 1-3.

The restriction requirement is not traversed.

RAEM Ref.: 2687-016DIV1 Date: July 30, 2004 PAGE 1/2 * RCVD AT 7/30/2004 1:41:20 PM (Eastern Daylight Time) * SVR:USPTO-EFXRF-U5 * DNIS:8728/2006 * CSID:405 922 1402 * DURATION (mim-ss):00-50

ELECTION Apple. No. 10/074,009

PATENT APPLICATION

In view of the above elections and identification of the generic claims, Applicant respectfully submits that claims 1, 4, 7, and 28-30 are elected for immediate examination. Claim 4 recites limitations unique to the elected species and claims 1, 7, and 28-30 are generic.

Claims 34 and 37-45 are to be withdrawn as corresponding to the non-elected Invention II, claim 5 is to be withdrawn (subject to possible rejoinder) as corresponding to the non-elected Species 2, and claim 6 is to be withdrawn (subject to possible rejoinder) as corresponding to the non-elected Species 3. It is understood that claim 31 recites a Markush group that includes limitations unique to the non-elected species, however, rejoinder of claim 31 would be appropriate if those limitations were to be deleted, or if a generic claim becomes allowed.

No fee is believed to be due. However, in the event it is determined that a fee is required for consideration of this paper, please charge any necessary fee to Deposit Account No. 19-1579.

Respectfully submitted,

ROBERTS ABOKHAIR & MARDULA, LLC

Kavin L. PONTIUS Reg. No. 37512

(505) 922-1400

Date: July 30, 2004 - 2 - Acty. Dkt. No.: 2687-016DIV1
PAGE 22'RCVD AT 7792004 1:41:20 PM [Eastern Daylight Time] * SVR:USPTO-EFXTF-U5 * DHS:872906* CSD:505 922 1402 * DURATION (mm-ss):00-60